A new U.S. clinical trial will evaluate whether an at-home, self-collection technique to screen for cervical cancer is as accurate and effective as a Pap smear test done in a healthcare clinic. The Clinical Monitoring Research Program Directorate (CMRPD) at the Frederick National Laboratory for Cancer Research will coordinate the National Cancer Institute (NCI) study to be conducted at 25 sites.

Scientists at the Frederick National Laboratory for Cancer Research (FNL) and their National Cancer Institute colleagues have developed a method that enhances the capacity to identify interactions between proteins and molecules that are critical to drug targeting. The study, reported in Science Advances, includes libraries to aid other researchers.

The Frederick National Laboratory for Cancer Research (FNL) has a new installation: a wall featuring 34 plaques highlighting patents granted to FNL researchers in recognition of their inventions and the breakthrough work being done at the laboratory. The “Innovations in Research” wall represents the mission of FNL staff to address some of the most urgent challenges in the biomedical sciences.

The lockdowns during 2020, the first year of the COVID-19 pandemic, temporarily paused most laboratory work, but they didn’t stop science from moving forward. Many scientists, including those comprising what’s now NCI’s Center for Structural Biology (CSB), seized the opportunity while out of the lab to revisit previously collected data. Those efforts are paying off.

Most available antibody-drug conjugates offer limited improvement and can still be toxic. But a study conducted by researchers in the National Cancer Institute’s Center for Cancer Research and published in Cell Reports in December 2023 highlights a new ADC—carefully engineered, screened, and purified—that can eradicate large tumors in animal models at a dose per body weight that humans can tolerate.